Development of Dapagliflozin Solid Lipid Nanoparticles as a Novel Carrier for Oral Delivery: Statistical Design, Optimization, In-Vitro and In-Vivo Characterization, and Evaluation

• Egile Nagusiak: Aziz Unnisa (Egilea), Ananda K. Chettupalli (Egilea), Turki Al Hagbani (Egilea), Mohammad Khalid (Egilea), Suresh B. Jandrajupalli (Egilea), Swarnalatha Chandolu (Egilea), Talib Hussain (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Controlling hyperglycemia and avoiding glucose reabsorption are significant goals in type 2 diabetes treatments. Among the numerous modes of medication administration, the oral route is the most common. Introduction: Dapagliflozin is an oral hypoglycemic agent and a powerful, competitive, reversible...